Concepedia

Author

Ullrich Graeven

Kliniken Maria HilfORCID

Also Known As

Eva Lengfelder, Graeven, Ullrich, Thomas Kittner, U Graeven, U. Graeven, U. Kania, ULLRICH GRAEVEN, Ullrich Graeven

294

Publications

8.8K

Citations

44

H-Index

74

Concepts

All Affiliations

Kliniken Maria HilfHeidelberg UniversityGerman Cancer Research CenterRuhr University BochumUniversity Hospital Heidelberg
UG

About

Ullrich Graeven is an author at Kliniken Maria Hilf specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

28

44

4.4K

2

Health Sciences

13

14

670

3

Cell Biology

7

7

509

4

Allergy

1

1

13

5

Blood Transplantation

1

1

67

Ullrich Graeven

×

89

Publications

7.7K

Citations

42

H-Index

YearCitations

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

Claus Rödel, Ullrich Graeven, Rainer Fietkau,

The Lancet Oncology

2015

713

Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial

Claus Rödel, Torsten Liersch, Heinz Becker,

The Lancet Oncology

2012

694

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin

Jim Cassidy, Chris Twelves, Eric Van Cutsem,

Annals of Oncology

2002

521

Vascular Endothelial Growth Factor, a Possible Paracrine Growth Factor in Human Acute Myeloid Leukemia

Walter Fiedler, Ullrich Graeven, Süleyman Ergün,

Blood

1997

446

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

Eric Van Cutsem, Paulo M. Hoff, Peter Harper,

British Journal of Cancer

2004

396

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Dominik Paul Modest, Ingrid Ricard, Volker Heinemann,

Annals of Oncology

2016

334

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

Rainer Porschen, Hendrik‐Tobias Arkenau, S. Kubicka,

Journal of Clinical Oncology

2007

278

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

Susanna Hegewisch‐Becker, Ullrich Graeven, Christian Lerchenmüller,

The Lancet Oncology

2015

246

5-Fluorouracil induces arterial vasocontractions

T Südhoff, M. Enderle, Michaela Pahlke,

Annals of Oncology

2004

165

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

Christian Buske, Eva Hoster, Martin Dreyling,

Leukemia

2008

155

Page 1